- Details
- In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....
|
- Details
- Oliver Sartor and Alicia Morgans discuss the TRITON 3 clinical trial. TRITON 3 is a phase three clinical trial observing how patients with metastatic castration-resistant prostate cancer with a homologous recombination gene deficiency respond to treatment with rucaparib versus treatment with a physician’s choice of abiraterone, enzalutamide, or docetaxel. Results found that rucaparib improved radi...
|
- Details
- Alicia Morgans speaks with Jeff Tosoian, PCF Young Investigator Award recipient, about his groundbreaking work on developing minimally invasive tactics to understand aggressive cancers. Dr. Tosoian, along with his multidisciplinary team, is keenly focused on creating a urine-based approach that could potentially revolutionize the process of diagnosing high-grade prostate cancer. The team has ident...
|
- Details
- In this discussion between Alicia Morgans and Alexander Wyatt, the two delve into the complexities of using circulating tumor DNA (ctDNA) in the treatment of prostate cancer. Dr. Wyatt explains the advantages of ctDNA in the metastatic setting, highlighting its minimally invasive nature and ease of collection compared to tissue biopsy. He emphasizes the importance of timing and patient selection i...
|
- Details
- Alicia Morgans interviews Nick Zorko, who shares his excitement about his team's work on natural killer (NK) cell therapies, specifically focusing on engineered NK cells to target the tumor marker B7-H3. Unlike most T-cell based approaches, this project aims at treating prostate cancer with modified NK cells. Their modifications include adding a chimeric antigen receptor specific for B7-H3 and par...
|
- Details
- At the 29th Annual Prostate Cancer Foundation Scientific Retreat, Alicia Morgans invites Philip Kantoff to introduce Convergent Therapeutics. Dr. Kantoff shares how the clinical-stage radiopharmaceutical company was developed, his role in the company, and future developments on the horizon. Convergent Therapeutics is focused on developing next-generation radiopharmaceutical therapies for prostate...
|
- Details
- At the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat Dr Saul Priceman joins Alicia Morgans in a discussion on clinic-ready CAR T cell therapies for Metastatic castrate-resistant prostate cancer (mCRPC) that can overcome the limitations of prior CAR T cell products for prostate cancer. Dr. Priceman highlights the role of PCF's funds in impacting these research efforts. The project...
|
- Details
- In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis. Simpa Salami is a Prostate Cancer Foundation (PCF) Young Investigator Award recipient. Highlighting key takeaways from two research studies, Dr. Salami also shares how the PCF funding has supported this r...
|
- Details
- In this conversation, Alicia Morgans and Alan Bryce highlighted the TRITON3 study. TRITON3 is a Phase 3, multicenter, open-label, randomized trial of Rubraca in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 405 patients with a mutation in BRCA or ATM who were randomized to Rubraca or the control group, which consisted of the physician’...
|
- Details
- In this conversation Charles Ryan and Kosj Yamoah discuss the importance of attention to disparities in prostate cancer care delivery. They reflect back on how far the field has come in this space highlighting Kosj Yamoah's Young Investigator Award research which hypothesized a biological difference based on race will lead to disparities throughout the spectrum of the disease. Prostate cancer's di...
|
